Early discharge with virtual follow-up for low-risk STEMI patients
Official title: Virtual Ward-Assisted Very earLy dIschArge of Low-rIsk STEMI patieNTs: the VALIANT-STEMI Trial
Run by The Leeds Teaching Hospitals NHS Trust · NCT06731257 · Data updated 2026-11-12
This study is testing if low-risk heart attack patients can safely go home within 24 hours and have follow-up care by phone instead of staying in the hospital longer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | The Leeds Teaching Hospitals NHS Trust Academic / other |
| Locations | 1 site (Leeds) |
| Status | Recruiting |
| Started | June 24, 2024 |
| Main results expected | March 2026 |
| Study ends | March 2026 |
| Registry record updated | December 12, 2024 |
| Trial ID | NCT06731257 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are low-risk STEMI patients who have successfully undergone revascularization and meet specific inclusion criteria.
✕Probably not a fit
Patients with significant comorbidities or those unable to manage home monitoring will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial investigates the safety and feasibility of early discharge (within 24 hours) for low-risk patients who have undergone successful treatment for ST elevation myocardial infarction (STEMI). Participants will be randomized to receive either standard care or early discharge with virtual follow-up via telephone. The primary outcome will be hospital readmission or all-cause mortality within 30 days post-discharge. The goal is to determine if this approach can reduce hospital stay while maintaining patient safety and well-being.
Why it matters
Potential benefit: If successful, this approach could lead to shorter hospital stays and improved patient satisfaction without compromising safety.
How similar studies have gone: While observational studies suggest early discharge is safe for low-risk patients, this randomized controlled trial approach is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Successful revascularisation following STEMI * Zwolle score \<=3 * No bystander disease awaiting inpatient intervention at the time of screening or consent (so if they have had intervention to a bystander vessel before this they would be eligible) Exclusion Criteria: * Haemodynamic instability (Killip class \>I) * Left ventricular ejection fraction \<45%\<40% * Sustained ventricular or atrial arrhythmias requiring intervention * No support at home or social or physical circumstances preventing early discharge * Unable to use home monitoring equipment * Unwilling to consent or follow instructions * Patients visiting from out of our catchment area * Out-of hospital cardiac arrest * Patients repatriated to their local hospital within 24 hours * New or worsening renal failure (i.e. creatinine \>=1.5x baseline)
Where it's running
-
Leeds Teaching Hospital NHS Trust
Leeds, United Kingdom Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Scar placement over the tumour versus hidden locations in breast-conserving surgery
This project will test whether placing the scar over the tumour versus in hidden locations changes patient satisfaction and clinical outcomes for women having standard breast-conserving surgery for breast cancer.
-
Online resilience training program for people with Multiple Sclerosis to help prevent job loss
This study is testing an online program to help people with Multiple Sclerosis build resilience and confidence to prevent job loss.
-
Observational study on newly diagnosed axial spondyloarthritis in the UK
This study looks at how being diagnosed later with axial spondyloarthritis affects work and daily life for people in the UK who have just been diagnosed and haven’t started biologic treatment yet.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.